Optimize Lead Choice
Make decisions preclinically when comparing & combining cell therapies with new modalities1
Apply the power of polyfunctional strength to identify functional immune cell subsets which correlate with in vivo activity.
How our Award-Winning IsoLight Single-Cell System is Making a Difference
Solution
PSI revealed differences in control and new combination therapy, enhancing decision making
Finding
NKTR-214 elicited more polyfunctional subsets than IL-2, which correlates with results from complementary technologies
Follow Our Data
See the latest published data in Checkpoint & Combination Immunotherapies
Polyfunctionality and Polyfunctional Strength are considerably increased in samples treated with ACT+NKTR-214 vs ACT+IL-2. Sorted antigen-specific CD8+ T cells Thy1.+ from tumors and spleen D7 after ACT+NKTR-214 or ACT+IL-2 (3 mice/group) were stimulated and stained with anti-mouse CD8.
NKTR2-14 elicited more polyfunctional cell subsets in the adoptively transferred TCR-T cells in spleen and tumor compared to IL-2.
Solution
IsoPlexis finds critical differences
Immuno-PET imaging using cys-diabody (cDb) targeting CD8 in vivo shows significant T cells expansion in spleen for ACT+NKTR-214-treated mice. Representative CD8 cys-diabody immuno-PET/CT images acquired on D5 after treatment with ACT+IL-2 or ACT+NKTR-214 (n=3/group). I.V. injection of Zr-89 labeled anti-CD8 cDb was performed 24h prior imaging of C57/BL6 mice.
NKTR-214 increases expression of genes associated with T cell cytotoxicity and memory. Clustering of chemokines and their receptors, showing a general trend of increased expression in the ACT+NKTR-214 group.1
[1] Reference: Parisi et al, AACR Annual Meeting 2018